Imperial Enterprise

Lizard venom to obesity drugs. Malaria parasites to billion-dollar cancer treatments.

We’ve been bringing Imperial’s stories to life.

Imperial Enterprise sits behind an extraordinary range of research, companies and partnerships. The challenge wasn’t finding things to say. It was showing just how much is happening without losing the stories that make it matter.

Moving quickly from the unexpected to the enormous. A scientific discovery becomes a treatment. A treatment becomes a company. A company becomes a deal worth billions.

The long chain

A $1.5bn exit makes a headline. The story behind it runs for more than twenty years, from malaria research to re-engineered cancer drugs.

What comes next

Imperial researchers are putting AI to work on problems that matter — predicting disease from ECG data, understanding new materials and changing how products are engineered.

Impact doesn’t always arrive as a company.

Research can change the air people breathe, the evidence governments act on and the health of whole communities. Imperial’s work reaches well beyond the lab.

Painting a story by numbers

Spinouts. Investment. Licences. Consultancy. Jobs. Students becoming founders. Companies working with Imperial across the world.

Businesses tackling cancer, stroke rehabilitation, sustainable chemistry, engineering, food, disease prediction and problems that haven’t been solved yet.

Behind every spinout.

Imperial runs nearly forty programmes and services, each covering a different chapter of the story.

Growing pains

New ventures need somewhere to grow. Imperial is building the infrastructure in West London for the next generation of researchers, founders and companies to take the story further.